Iloperidone for the Management of Adults with Schizophrenia

Clinical Therapeutics

Volumn 33, Issue 3, 2011, Pages 330-345

  Crabtree, Brian L ^a,b,c   Montgomery, John ^c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c Mississippi State Hospital   (United States)

Author keywords

Antipsychotic drugs; Iloperidone; Schizophrenia; Second generation antipsychotics

Indexed keywords

AMIODARONE; ANTIHYPERTENSIVE AGENT; APOMORPHINE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIRAZOLINE; FLUOXETINE; HALOPERIDOL; ILOPERIDONE; KETOCONAZOLE; OLANZAPINE; PAROXETINE; PHENCYCLIDINE; PLACEBO; PRAZOSIN; PROCAINAMIDE; RISPERIDONE; TERAZOSIN; THIORIDAZINE; ZIPRASIDONE;

ADULT; AGED; AGITATION; ANXIETY; ANXIETY DISORDER; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DEMENTIA; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; MALE; MEDLINE; MOOD DISORDER; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; ISOXAZOLES; PIPERIDINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 79956044939     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.03.006     Document Type: Article

References (33)

1. Pompili M., Amador X.F., Girardi P., et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry 2007, 6:10.
2. Regier D.A., Narrow W.E., Rae D.S., et al. The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993, 50:85-94.
3. Rupp A., Keith S.J. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am 1993, 16:413-423.
4. Stan A.D., Lesselyong A., Ghose S. Cellular and molecular neuropathology of schizophrenia. Kaplan and Sadock's Comprehensive Textbook of Psychiatry 2009, 1487-1494. Lippincott Williams & Wilkins, Philadelphia. 9th ed. B.J. Sadock, V.A. Sadock, P. Ruiz (Eds.).
5. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005, 353:1209-1223.
6. Jones P.B., Barnes T.R.E., Davies L., et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Genl Psychiatry 2006, 63:1079-1087.
7. Strupczewski J.T., Bordeau K.J., Chiang Y., et al. 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem 1995, 38:1119-1131.
8. Szczepanik A.M., Brougham L.R., Roehr J.E., et al. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity. J Pharmacol Exp Ther 1996, 278:913-920.
9. Corbett R., Griffiths L., Shipley J.E., et al. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev 1997, 3:120-147.
10. Hesselink J.M.K. Iloperidone. IDrugs 2002, 5:84-90.
11. Szewczak M.R., Corbett R., Rush D.K., et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Expl Ther 1995, 274:1404-1413.
12. Kongsamut S., Roehr J.E., Cai J., et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996, 317:417-423.
13. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999, 249(Suppl 4):90-98.
14. Kalkman H.O., Subramanian N., Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001, 25:904-914.
15. Kroeze W.K., Hufeisen S.J., Popadak B.A., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526.
16. Costall B., Naylor R.J., Nohria V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol 1978, 50:39-50.
17. Barr A.M., Powell S.B., Markou A., Geyer M.A. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 2006, 51:457-465.
18. Braff D.L., Geyer M.A., Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 2001, 156:234-258.
19. Sainati S.M., Hubbard J.W., Chi E., et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995, 35:713-720.
20. Iloperidone drug approval package: clinical pharmacology and biopharmaceutics review(s) U.S. Food and Drug Administration, Accessed August 27, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022192s000_ClinPharmR.pdf.
21. Fanapt (iloperidone) tablets Vanda Pharmaceuticals, Accessed April 25, 2011. http://www.fanapt.com.
22. Mutlib A.E., Klein J.T. Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Expl Ther 1998, 286:1285-1293.
23. Subramanian N., Kalkman H.O. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:553-560.
24. Cutler A.J., Kalali A.H., Weiden P.J., et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008, 28(Suppl 1):S20-S28.
25. Volpi S., Potkin S.G., Malhotra A.K., et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009, 70:801-809.
26. Lavedan C., Volpi S., Polymeropoulos M.H., Wolfgang C.D. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics 2008, 9:289-301.
27. Lavedan C., Licamele L., Volpi S., et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009, 14:804-819.
28. Potkin S.G., Litman R.E., Torres R., Wolfgang C.D. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008, 28(2 Suppl 1):S4-S11.
29. Kane J.M., Lauriello J., Laska E., et al. Long-term efficacy and safety of iloperidone. Results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008, 28(2 Suppl 1):S29-S35.
30. Weiden P.J., Cutler A.J., Polymeropoulos M.H., Wolfgang C.D. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008, 28(2 Suppl 1):S12-S19.
31. Thompson A., Lavedan C., Volpi S. Absence of weight gain association with the HTR2C-759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res 2010, 175:271-273.
32. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialized second-generation antipsychotic. Int J Clin Pract 2009, 8:1237-1248.
33. Hoffman B.B. Therapy of hypertension. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2006, 845-868. McGraw Hill, New York. 11th ed. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).